P 3298

Drug Profile

P 3298

Alternative Names: P-32-98; P32/98

Latest Information Update: 22 Feb 2008

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Probiodrug
  • Class Antihyperglycaemics; Thiazolidines
  • Mechanism of Action CD26 antigen inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Type 2 diabetes mellitus

Most Recent Events

  • 04 Dec 2002 Probiodrug has granted a non-exclusive licence to Ferring and its sublicensee, Ortho-McNeil Pharmaceuticals, for the inhibitors if dipeptidyl peptidase IV for diabetes and obesity
  • 06 Apr 2001 Phase-II clinical trials for Type-2 diabetes mellitus in Germany (PO)
  • 20 Feb 2001 A study has been added to the adverse events section
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top